Sign in Subscribe
Drugs

Trump Administration Prepares New Investigation for Pharmaceutical Tariffs

Strategic Insights

— 1 min read

The Trump administration is reportedly preparing an "imminent" probe to explore whether trade partners are not paying enough for medicines, which could result in additional import taxes. The investigation, under Section 301 of the Trade Act of 1974, would examine whether countries are charging too little for pharmaceuticals. This new probe comes as the administration has been pushing for lower drug prices, with President Donald Trump citing the need to align US prices with those in other developed nations.

Key Takeaways:

  • The US pays on average nearly three times higher for drugs than most other developed nations, according to a 2022 report by the nonprofit Rand Corporation.
  • The administration's MFN drug pricing push aims to align US medicine costs with lower prices in other comparator nations.
  • Three major pharmaceutical companies, Pfizer, Eli Lilly, and Merck KGaA's US arm, have inked formal MFN deals with the White House, agreeing to lower certain drug costs.
  • The companies have also won temporary reprieves from the administration's Section 232 tariffs.
  • Pharmaceutical companies have pumped billions of dollars into US manufacturing this year in response to the threat of trade duties.
  • Multiple other drugmakers, including Novo Nordisk, Thermo Fisher Scientific, and Teva Pharmaceutical Industries, are in discussions with the Trump administration about drug pricing reforms.

Statistics:

  • The US pays on average nearly three times higher for drugs than most other developed nations (Rand Corporation, 2022).
  • Pharmaceutical companies have invested billions of dollars in US manufacturing this year (estimated).
  • Three MFN deals have been inked with the White House, covering Pfizer, Eli Lilly, and Merck KGaA's US arm.
  • Temporary reprieves from Section 232 tariffs have been granted to the three companies that signed MFN deals.

Sources:

  • "White House to investigate whether emerging markets are not paying enough for medicines" by Christine Olley, reporting for the Financial Times, September 27, 2023.
  • "Trump administration walks back plans to impose 100% tariff on foreign pharmaceuticals" by Christine Olley, reporting for the Financial Times, October 1, 2023.

Read more